AstraZeneca’s (AZN) “Buy” Rating Reiterated at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a report issued on Wednesday,Digital Look reports. They presently have a £180 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target points to a potential upside of 32.02% from the stock’s current price.

A number of other analysts have also recently issued reports on AZN. Citigroup boosted their target price on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday, April 10th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and set a £115 price objective on shares of AstraZeneca in a research note on Wednesday, May 6th. Finally, Berenberg Bank raised their target price on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of £153.33.

AstraZeneca Trading Down 0.8%

Shares of AZN stock opened at £136.34 on Wednesday. The firm has a market cap of £211.44 billion, a P/E ratio of 20.53, a PEG ratio of 0.86 and a beta of 0.22. AstraZeneca has a 1-year low of GBX 9,932 and a 1-year high of £157.32. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The firm’s 50-day simple moving average is £144.48 and its 200-day simple moving average is £140.28.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.